Biochemistry laboratory shift based on common terminology criteria in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily: Results from the 42-month BOLT study

Main Article Content

Alexander Guminski
Peter Foley
Jean-Jacques Grob
Caroline Robert
Ralf Gutzmer
Nicholas Squittieri
Felix Kiecker

Keywords

sonidegib, basal cell carcinoma, biochemistry assessments, advanced basal cell carcinoma, Hedgehog pathway inhibitor, oncology

References

1. Cortes JE, et al. Cancer Treat Rev. 2019;76:41–50.

2. Kim JYS, et al. J Am Acad Dermatol. 2018;78(3):540–59.

3. Odomzo (sonidegib capsules). Full Prescribing Information. Sun Pharmaceutical Industries, Inc., Cranbury, NJ, USA.

4. European Medicines Agency. Summary of Product Characteristics, WC500188762. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002839/WC500192970.pdf.

5. Swissmedic, Authorization Number 65065, 2015. https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/authorisations/new-medicines/odomzo--200mg--kapseln--sonidegibum-.html.

6. Australian Government Department of Health, ARTG 292262. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2017-PI-02511-1&d=2018030216114622483.

7. Dummer R, et al. Br J Dermatol. 2020;182(6):1369–78.

8. Dummer R, et al. J Am Acad Dermatol. 2016;75(1):113–25.e115.

9. Lear JT, et al. J Eur Acad Dermatol Venereol. 2018;32(3):372–81.

10. Migden MR, et al. Lancet Oncol. 2015;16(6):716–28.

11. Health UDo, Services H. Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health, National Cancer Institute. 2009;4(03).

Most read articles by the same author(s)

1 2 3 > >>